Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

University of Kansas Medical Center · NCT07242118

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 65+ · Women only
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
18
US sites recruiting
1
Study start
November 4, 2025
Record last updated
February 10, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This phase II study evaluates SABR as non-operative treatment for women aged 65+ with ER-positive, HER2-negative breast cancer ≤5 cm and no lymph node involvement. Eligible patients, including those previously on endocrine therapy, receive 5 SABR treatments, followed by monitoring of quality of life and assessment of treatment-related toxicity.

Being studied: SABR

Conditions: Breast Cancer Female

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Willing and able to provide written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
  • Women greater than or equal to age 65 years
  • Diagnosis of invasive carcinoma of breast undergoing non-operative management
  • Previously untreated OR previously treated with primary ET or chemotherapy, with either stable or progressive localized disease.
  • Tumor measuring ≤5 cm (cT1-T2) and clinically node negative
  • Diagnostic biopsy ER-positive (greater than or equal to 10% ER by immunohistochemistry staining)
  • Diagnostic biopsy HER2-negative according to ASCO/CAP guidelines (0 or 1+ following IHC staining or proven negative by in-situ hybridization)
  • Suitable for SABR as deemed by the treating radiation oncologist
  • Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Enrollment in another clinical trial is allowed if there would be no interference with interventions on this trial

Exclusion Criteria

  • Active treatment with systemic chemotherapy for breast cancer. Subjects will need to stop any breast cancer chemotherapy agent before enrollment to be included study.
  • Multicentric tumor.
  • Clinical or imaging evidence of distant metastases.
  • Prior ipsilateral breast or thoracic radiation.
  • Autoimmune conditions with associated radiation risks.

Recruiting US locations

  • University of Kansas Medical Center

    Kansas City, KS 66160

    Site contact: Rachel Clinical Research Coordinator · 913-588-6249 · rheueisen@kumc.edu

Study contacts (from the official record)

  • Amanda Project Manager · 913-588-1617 · aschroeder3@kumc.edu
  • Rachel Clinical Research Coordinator · 913-945-6955 · rheueisen@kumc.edu
All healthy volunteers studies in Kansas →
Conformal Ablative Radiotherapy in Older Women (CARMEN) With… (NCT07242118) | Bored Studies